Table 1.
Overview of benefits and AEs in clinical trial involving FGFR inhibitors in urothelial carcinoma.
| Drug | Family | Phase | FGFR based eligibility | Dosage | Prior ICIs | Most common AEs | ORR |
|---|---|---|---|---|---|---|---|
| Erdafitinib | FGFR1-4 inhibitor | I | No selection with genomic tests | 10 mg/day 7-days-on/7-days-off | - | Hyperphosphatemia (65%) Asthenia (55%) Dry mouth (45%) Decreased appetite (38%) |
3/8 had PRs (among patients with UC harbouring FGFR2 or FGFR3 fusions) |
| II | Any FGFR alteration | 8 mg daily (up to 9 mg) | 22% | Hyperphosphatemia (69%) Skin and nail AEs (66%) Eye AEs (57%) Stomatitis (47%) |
40% | ||
| Rogaratinib | FGFR1-4 inhibitor | I | FGFR over-expression/ mutation | 800 mg twice daily | 30% | Diarrhea (61%) Nail disorders (52%) Hyperphosphatemia (45%) |
23% |
| Infigratinib | pan-FGFR inhibitor | I | FGFR3 alteration | 125 mg/day 3 weeks on/1 week off | 16% | Diarrhea (61%) Nail disorders (52%) Hyperphosphatemia (45%) |
25.4% |
| Vofatamab | Human anti-FGFR3 monoclonal Ab | Ib/II | FGFR3 alteration | 25 mg/kg q21 | - | Fatigue (12%) Nausea (12%) |
4/10 had SD |
AE, adverse events; FGFR, fibroblast growth factor receptor; ICIs, immune checkpoint inhibitor; ORR, overall response rate; PRs, partial responses, SD, stable disease.